PDE-5 inhibitors increase risk of biochemical recurrence after radical prostatectomy

the ONA take:

According to a new study published in The Journal of Urology, researchers have found that taking phosphodiesterase type 5 inhibitors following radical prostatectomy is associated with an elevated risk of biochemical recurrence.

Phosphodiesterase type 5 inhibitors include sildenafil, tadalafil, and vardenafil, and are indicated for the treatment of pulmonary hypertension and erectile dysfunction. 

Researchers at University Hospital Hamburg-Eppendorf in Hamburg, Germany, sought to investigate the effect of phosphodiesterase type 5 inhibitors on biochemical recurrence following a radical prostatectomy in patients with prostate cancer.

Researchers analyzed data from nearly 5,000 patients with localized prostate cancer who underwent bilateral nerve-sparing radical prostatectomy. Of those, 23.4% used phosphodiesterase type 5 inhibitors following surgery. 

During a median follow-up of 60.3 months, there was a 5-year biochemical recurrence-free survival of 84.7% in the phosphodiesterase type 5 inhibitor group compared with 89.2% in the nonphosphodiesterase type 5 inhibitor group. Multivariate analysis showed that phosphodiesterase type 5 inhibitor use was an independent risk factor for biochemical recurrence (HR = 1.38).

PDE-5 inhibitors increase risk of biochemical recurrence after radical prostatectomy
Taking phosphodiesterase type 5 inhibitors following radical prostatectomy is associated with an elevated risk of recurrence.
Phosphodiesterase type 5 inhibitor use after radical prostatectomy is associated with increased risk of biochemical recurrence, according to a study published in the February issue of The Journal of Urology.
READ FULL ARTICLE From Medical Express
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs